Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study.

Cancer chemotherapy and pharmacology - 1 Nov 2010

Fariña-Sarasqueta Arantza, van Lijnschoten Gesina, Rutten Harm J T, van den Brule Adriaan J C

Abstract excerpt

PURPOSE: The role of pharmacogenetics in chemotherapy response in colon carcinoma is controversial. We studied the value of known SNPs in genes involved in 5-FU metabolism as biomarkers of chemotherapy response in patients with stage III colon carcinoma. METHODS: DNA was isolated from normal colonic tissue of 60 patients with stage III colon carcinoma treated adjuvantly with 5-FU combined with leucovorin. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colonic Neoplasms

Share to Disease-Free Survival

Share to Fluorouracil

Share to Kaplan-Meier Estimate

Share to Neoplasm Staging

Share to Pilot Projects

Source

Identifiers

PMID: 20665215
DOI: 10.1007/s00280-010-1403-0

Genes

DPYD
TYMP
TYMS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study.PMID 20665215Read ↗

TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.Semantic proximity Read ↗

TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.Semantic proximity Read ↗

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patientsSemantic proximity Read ↗

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.Semantic proximity Read ↗

Investigation of DPYD, MTHFR and TYMS polymorphisms on 5-fluorouracil related toxicities in colorectal cancer.Semantic proximity Read ↗

Role of Single-Nucleotide Polymorphisms in Genes Implicated in Capecitabine Pharmacodynamics on the Effectiveness of Adjuvant Therapy in Colorectal Cancer.Semantic proximity Read ↗

Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.Semantic proximity Read ↗

Implication of TYMP genetic variation on the prognosis of patients with colorectal cancer who received capecitabine-based adjuvant chemotherapy after surgical resection: a real-world exploratory studySemantic proximity Read ↗

Thymidylate synthase gene variants as predictors of clinical response and toxicity to fluoropyrimidine-based chemotherapy for colorectal cancer.Semantic proximity Read ↗

Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis.Semantic proximity Read ↗

The role of pharmacogenetics in capecitabine efficacy and toxicity.Semantic proximity Read ↗

The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.